Lindsell, Christopher J.
McGlothlin, Anna
Nwosu, Samuel
Rice, Todd W.
Hall, Alex
Bernard, Gordon R.
Busse, Laurence W.
Ely, E. Wesley
Fowler, Alpha A.
Gaieski, David F.
Hinson, Jeremiah S.
Hooper, Michael H.
Jackson, James C.
Kelen, Gabor D.
Levine, Mark
Martin, Greg S.
Rothman, Richard E.
Sevransky, Jonathan E.
Viele, Kert
Wright, David W.
Hager, David N.
Funding for this research was provided by:
Marcus Foundation
Nova Biomedical
Article History
Received: 19 March 2020
Accepted: 28 March 2020
First Online: 22 April 2020
Ethics approval and consent to participate
: The VICTAS study was approved by a central IRB (Johns Hopkins University IRB protocol number: IRB00164053). Each site’s local IRB approved the Informed Consent Document for local use and formally relied on this central approval before enrollment proceeded at that site. This study is registered with ExternalRef removed as NCT03509350.
: CJL reports funding for the VICTAS trial to his institution from the Marcus Foundation, grants, and contracts to his institution from the National Institutes of Health and Endpoint Health and is named as co-inventor on patents related to risk stratification in septic shock. AM and KV are salaried employees of Berry Consultants, which is under contract with Emory University to support the design work and execution of the VICTAS trial. AH reports funding for the VICTAS trial to his institution from the Marcus Foundation as well as grants from the National Institutes of Health (NIH), Cerenovus, Sense Diagnostics, and the NICO Corporation. SN, GRB, DNH, JSH, REM, TR, and RER report funding for the VICTAS trial to their institutions from the Marcus Foundation. EWE reports funding for the VICTAS trial to his institution from the Marcus Foundation and has received honoraria from Pfizer, Orion, and Masimo for continuing medical education activities (no speakers’ bureaus or stocks, etc.). ML is supported by the Intramural Research Program, NIDDK, NIH. DK053212–12: Ascorbic acid as a pharmacologic agent in disease treatment. GSM reports grants for the VICTAS Trial to his institution from the Marcus Foundation as well as grants from National Institutes of Health (NIH), Biomedical Advanced Research and Development Authority (BARDA) and Bristol-Myers Squibb to his institution. JES reports grants for the VICTAS trial to his institution from the Marcus Foundation, funding from the Biomedical Advanced Research and Development Authority, and a stipend from the Society of Critical Care Medicine to support his editorial position for the journal <i>Critical Care Medicine</i>. DWW reports the grant for the VICTAS trial to his institution from the Marcus Foundation as well as grants from the National Institutes of Health (NIH), the National Highway Transportation Safety Administration, the Department of Defense, NICO Corporation, and the Centers for Disease Control and Prevention.